^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
Published date:
05/11/2023
Excerpt:
In contrast, TP53mut patients (n=12/109) had increased sensitivity to A-1331852 (Figure A), and the dual BCL-2/BCL-XL inhibitor navitoclax was highly effective in TP53mut blasts when compared to single agents venetoclax and A-1331852 (Figure B).
Trial ID:
